A novel synthesis of tert-leucine via a Leuckart type reaction
作者:Brian M. Adger、Ulrich C. Dyer、Ian C. Lennon、Peter D. Tiffin、Simon E. Ward
DOI:10.1016/s0040-4039(97)00269-4
日期:1997.3
An efficient synthesis of racemic tert-leucine from trimethylpyruvic acid using a Leuckart type reaction is described. A facile resolution of an intermediate with α-methylbenzylamine allows entry into either (R)-or (S)-tert-leucine.
.alpha.-oximino carboxylic acids or their esters are reduced with an alkali boron hydride and hydrogen chloride or sulfuric acid to yield racemic amino alcohols (e.g. (RS)-tert-leucinol).
Catalytic oxidation of 3,3-dimethyl-2-hydroxybutyric acid to 2-oxo acid
申请人:Mobay Chemical Corporation
公开号:US04614822A1
公开(公告)日:1986-09-30
Sodium 3,3-dimethyl-2-hydroxybutyrate and ruthenium dioxide hydrate are added to water, the pH rendered alkaline, and sodium hypochlorite is slowly added to produce sodium 3,3-dimethyl-2-oxobutyrate in high yield and purity. The solid catalyst is filtered off and may be re-used while the filtrate can be directly used in further synthesis.
Method of producing optically active tert-leucinol and its use
申请人:Degussa Aktiengesellschaft
公开号:US05723667A1
公开(公告)日:1998-03-03
A method of producing optically active tert-leucinol (formula I) of high enantiomeric purity ##STR1## by converting racemic (RS)-tert-leucinol into a diastereomeric salt pair by reaction with an optically active acid, removing the salt pair from solution by fractionated crystallization and separating therefrom the optically active acid to release the optically active tert-leucinol from the salt. The optically active acid used is an N-acylated tert-leucine of general formula VIII: ##STR2## in which R can be hydrogen or an alkyl-, arylalkyl- or aryl group with up to 20 C atoms and * signifies a chirality center.
The present invention relates to a compound represented by the formula:
wherein Ar is a phenyl group optionally having substituent(s), R
1
is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), R
2
is a hydrogen atom, a C
1-6
alkyl group optionally having substituent(s) or a C
3-6
cycloalkyl group optionally having substituent(s), Z is a methylene group optionally having a C
1-6
alkyl group, ring A is a piperidine ring optionally further having substituent(s), ring B and ring C are benzene rings optionally further having substituent(s), and R
2
optionally form a ring together with the adjacent substituent on the ring B, except the compounds represented by the formula:
or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as a pharmaceutical agent, for example, tachykinin receptor antagonist, an agent for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases.